综合老年评估在澳大利亚老年弥漫大B细胞淋巴瘤患者接受利妥昔单抗联合化疗中的效用
该研究回顾性分析了2009至2016年3家三级医院205例年龄≥60岁的新诊断弥漫大B细胞淋巴瘤患者,描述利妥昔单抗联合化疗的毒性及回顾性基线综合老年评估(CGA)的预测效用。
要点
- CGA-fit、CGA-unfit、CGA-frail患者3年OS分别为82%、60%、53%。
核心结论
- CGA与基线预防性减量相关,但未预测≥3级毒性、≥2次非计划入院或后续减量。
- CGA-fit患者OS优于CGA-frail患者,PFS差异无统计学意义。
- 基线减量和早期终止治疗与较差OS和PFS独立相关(独立于CGA)。
研究设计与样本
- 回顾性研究,纳入2009至2016年3家三级医院205例新诊断DLBCL且年龄≥60岁患者。
- 回顾性分配基线综合老年评估(CGA),分析其与毒性的预测效用。
主要发现
- 41%(82/201)在周期1后需要减量,23%(39/166)化疗延迟,13%(26/198)早期终止治疗。
- CGA-fit、CGA-unfit、CGA-frail患者3年OS分别为82%、60%、53%。
- CGA-fit、CGA-unfit、CGA-frail患者3年PFS分别为66%、58%、46%。
临床怎么用
- CGA可用于识别老年DLBCL患者中OS较差的风险群体(CGA-frail)。
- 基线减量和早期终止治疗与不良生存独立相关(独立于CGA)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elderly patients may be heterogeneous in their abilities to tolerate immunochemotherapy-associated toxicities. We describe the morbidity of rituximab-chemotherapy combinations among 205 newly-diagnosed diffuse large B-cell lymphoma (DLBCL) patients aged ≥60 years from 3 tertiary hospitals between 2009 and 2016, and explore the utility of retrospectively-assigned baseline Comprehensive Geriatric Assessment (CGA) in predicting these toxicities. Seventy-three percent (146/201) experienced grade ≥3 toxicities, 81% (163/201) needed admission, 52% (107/205) had ≥2 unplanned admissions, 82/201 (41%) required dose reductions (DR) subsequent to Cycle 1, 39/166 (23%) had chemotherapy delays and 26/198 (13%) ceased therapy early. CGA was associated with pre-emptive baseline DR and perhaps because of this, did not predict grade ≥3 toxicities, ≥2 unplanned admissions or subsequent DR. Three-year overall survival (OS) of CGA-fit, CGA-unfit and CGA-frail patients was 82%, 60% and 53%, respectively. Three-year progression-free survival (PFS) of CGA-fit, CGA-unfit and CGA-frail patients was 66%, 58% and 46%, respectively. OS of CGA-fit patients was not statistically different from CGA-unfit patients, but was superior to CGA-frail patients (hazard ratio 2·892, 95% confidence interval 1·275-6·559, P = 0·011). PFS differences were not statistically significant. Baseline DR and early therapy cessation were associated with inferior OS and PFS independent of CGA. Prospective studies are needed to confirm if CGA-adapted treatment strategies minimize morbidity and improves survival.
引用
- Ong DM, Ashby M, Grigg A, et al. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations. Br J Haematol. 2019. PMID: 31206608. doi:10.1111/bjh.16049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。